BRIEF—Grifols' launch plans for Tavlesse in Europe and Turkey

The European Commission has approved USA-based Rigel Pharmaceuticals’ Tavlesse (fostamatinib) for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.

Spanish drugmaker Grifols has exclusive rights to fostamatinib in chronic ITP, as well as any potential future indications like autoimmune hemolytic anemia (AIHA), and IgA nephropathy (IgAN), in Europe and Turkey.

Currently, fostamatinib is commercially available in the USA under the brand name Tavalisse, which is the first and only SYK (spleen tyrosine kinase) inhibitor indicated in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

The launch of Tavlesse is expected to be in second quarter of this year, and complements Grifols’ product portfolio and would benefit patients and offer more therapeutic options for healthcare professionals, the company states.